GO
Loading...

Medicine

More

  • Study: Removing clot helps limit stroke disability Wednesday, 17 Dec 2014 | 2:02 PM ET

    For the first time in two decades, a new treatment has been shown to limit the damage from a common type of stroke. Researchers in the Netherlands found that mechanically removing a clot in addition to using a standard clot-busting medicine lowered the risk that a stroke sufferer would end up seriously disabled. In fact, three studies published last year in the...

  • Bird flu found in wild birds in Washington state - USDA Wednesday, 17 Dec 2014 | 12:18 PM ET

    Dec 17- Two strains of avian influenza have been confirmed in wild birds in Washington state, near the U.S. border with Canada, but there is no immediate cause for public health concerns, U.S. agriculture officials said on Wednesday. The other strain, H5N8, was found in captive gyrfalcons that were fed hunter-killed wild birds, the USDA said. Neither virus has been...

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...

  • EXCLUSIVE-Amgen leukemia drug to carry $178,000 price tag Wednesday, 17 Dec 2014 | 11:28 AM ET

    Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available this month, which would make it one of the world's most expensive cancer drugs. Company spokeswoman Danielle Bertrand said the price for the infused medicine, called Blincyto, would reflect two courses of treatment, at...

  • Dec 16- Shares of Auspex Pharmaceuticals Inc soared about 60 percent on Tuesday after the drug developer said its product for treating chorea, or involuntary movement associated with Huntington's disease, met the main goal in a late-stage study. The shares jumped about to $40 in extended trading after closing at $25.09 on Nasdaq. The company said it was also...

  • Dec 16- Cyclacel Pharmaceuticals Inc said an independent committee had determined that its lead drug was unlikely to show a statistically significant improvement in the survival rates in some leukemia patients. The company's stock plunged nearly 69 percent to 89 cents in premarket trading on Tuesday. The Berkeley Heights, New Jersey- based company's stock...

  • Indoor tanning injuries can require ER treatment Tuesday, 16 Dec 2014 | 6:51 AM ET

    CHICAGO— Indoor tanning injuries have declined but still sent more than 1,000 people to emergency rooms in recent years. Here's a look at what's billed as the first national estimate on these injuries, from the federal Centers for Disease Control and Prevention:. "That is a safety record all industries should strive to achieve," said John Overstreet, head of the...

  • NY commuter rail takes step toward apnea screening Monday, 15 Dec 2014 | 12:20 PM ET

    NEW YORK— A year after a deadly derailment that was blamed on an engineer's sleepiness, the Metro-North Railroad has chosen a contractor to test for sleep apnea. Metro-North said Monday that if the contract is approved, its 410 engineers and about 20 trainees will be screened for the disorder by the railroad's Occupational Health Services Department.

  • Dec 15- Sophiris Bio Inc lost about 80 percent of its market value after interim data showed that its only compound was not effective in treating lower urinary tract symptoms of enlarged prostate. Sophiris Bio, which had touted benign prostatic hyperplasia as a blockbuster indication, said the ongoing late-stage study of the drug was "unaffected" by the data.

  • Cancer patients testing drugs on mouse 'avatars' Monday, 15 Dec 2014 | 12:01 AM ET

    Scientists often test drugs in mice. Now some cancer patients are doing the same— with the hope of curing their own disease. It's the wave of the future, "said Eileen Youtie, a Miami woman using mice to guide care for her hard-to-treat form of breast cancer.

  • Bruce Aylward, the head of Ebola response at the World Health Organization, said Sierra Leone was well placed to contain the disease-- its worst outbreak on record-- with infrastructure, organization and aid. While neighboring Liberia has turned the tide of Ebola, and both Mali and Nigeria quickly smothered outbreaks, Sierra Leone has more than 70 percent of cases...

  • Atkins diet co-author sentenced to 41 months Friday, 12 Dec 2014 | 12:03 PM ET

    KANSAS CITY, Kan.— A Kansas obesity specialist who co-authored the "Atkins Diabetes Revolution" has been sentenced to three years and five months in federal prison for tax evasion, the U.S. attorney's office announced Friday. Vernon earned almost $800,000 by working for Atkins' nutrition and weight-loss companies from 2003 to 2008. Prosecutors said that from...

  • Dec 12- ChemoCentryx Inc's shares doubled in value premarket after the company said its experimental drug met the main goal of reducing excessive protein in urine in diabetics with progressive kidney disease after 52 weeks. A sustained reduction in albuminuria- excessive protein in the urine- was induced by the combination therapy, ChemoCentryx said.

  • Dec 12- ChemoCentryx Inc said a combination of its experimental drug and the standard-of-care regimen was found to be superior in diabetics with progressive kidney disease than standard treatment alone. The Mountain View, California- based company's shares jumped more than 39 percent to $6.25 in premarket trade on Friday. Diabetic nephropathy is the...

  • Avian flu spreading in southwest British Columbia Thursday, 11 Dec 2014 | 1:21 PM ET

    VANCOUVER, British Columbia— The avian influenza outbreak in southwest British Columbia's Fraser Valley has spread to seven farms, and 155,000 birds have died of the virus or will be euthanized, the Canadian Food Inspection Agency said. The outbreak began last week when turkeys and chickens at two farms in the Fraser Valley tested positive for the H5N2 strain...

  • Studies: Progesterone fails to help brain injuries Thursday, 11 Dec 2014 | 6:52 AM ET

    Giving people with fresh traumatic brain injuries the hormone progesterone does no good, two major studies have found. Brain injuries account for more than 2 million hospitalizations or emergency room visits each year in the United States and often cause major disabilities. In one, funded by the National Institutes of Health and led by doctors at Emory...

  • CHICAGO, Dec 10- Small startup NextCode Health will use gene-hunting tools pioneered by Iceland's Decode Genetics to help a leading U.S. pediatric hospital identify causes of rare diseases in children, marking the latest foray of genetic sequencing into routine medical practice. Cambridge, Massachusetts- based NextCode, a Decode spin-off, has signed a deal...

  • Gilead faces lawsuit over hepatitis C drug pricing Wednesday, 10 Dec 2014 | 5:59 PM ET

    HAVERFORD, Pa.— Philadelphia's Transportation Authority has filed a lawsuit against Gilead Sciences Inc. over the pricing of its hepatitis C drug. Gilead has been selling a 12- week treatment of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. The Foster City, California, company could not be reached immediately for a comment...

  • Gilead sued over 'exorbitant' hepatitis C drug prices Wednesday, 10 Dec 2014 | 3:55 PM ET

    Dec 10- Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc of charging "exorbitant" prices for its blockbuster hepatitis C drug Sovaldi. The lawsuit, filed Tuesday in federal court in Philadelphia by the Southeastern Pennsylvania Transportation Authority, seeks an unspecified amount of money damages.

  • New HPV vaccine strengthens cancer protection Wednesday, 10 Dec 2014 | 3:22 PM ET

    WASHINGTON— The drugmaker Merck& Co. Inc. has received approval for an updated version of its Gardasil vaccine that protects against an additional five strains of the virus that causes most cases of cervical cancer. The FDA said Wednesday the updated Gardasil has the potential to prevent roughly 90 percent of cervical, vulvar, vaginal and anal cancers.